Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 23, 2017

DrugPatentWatch Database Preview

Amlodipine besylate; valsartan - Generic Drug Details

« Back to Dashboard

What are the generic sources for amlodipine besylate; valsartan and what is the scope of amlodipine besylate; valsartan patent protection?

Amlodipine besylate; valsartan
is the generic ingredient in two branded drugs marketed by Par Pharm Inc, Aurobindo Pharma Ltd, Alembic Pharms Ltd, Novel Labs Inc, Teva Pharms Usa, Invagen Pharms, Lupin, Torrent Pharms Ltd, Mylan Pharms Inc, and Novartis, and is included in ten NDAs. There are three patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Amlodipine besylate; valsartan has eighty patent family members in thirty-three countries.

There are forty-nine drug master file entries for amlodipine besylate; valsartan. Fifteen suppliers are listed for this compound.

Summary for Generic Name: amlodipine besylate; valsartan

Drug Master File Entries: see list49
Suppliers / Packagers: see list15
Clinical Trials: see list193
Drug Prices:see low prices
DailyMed Link:amlodipine besylate; valsartan at DailyMed

Pharmacology for Ingredient: amlodipine besylate; valsartan

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alembic Pharms Ltd
amlodipine besylate; valsartan
TABLET;ORAL202713-002Apr 3, 2015ABRXNoNo► Subscribe► Subscribe
Mylan Pharms Inc
amlodipine besylate; valsartan
TABLET;ORAL090483-002Mar 30, 2015ABRXNoNo► Subscribe► Subscribe
Par Pharm Inc
amlodipine besylate; valsartan
TABLET;ORAL090011-002Mar 28, 2013ABRXNoNo► Subscribe► Subscribe
Teva Pharms Usa
amlodipine besylate; valsartan
TABLET;ORAL091235-002Mar 30, 2015ABRXNoNo► Subscribe► Subscribe
Novel Labs Inc
amlodipine besylate; valsartan
TABLET;ORAL202829-003Mar 30, 2015ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Formulary management
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus